<DOC>
	<DOCNO>NCT01632241</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability belimumab adult patient black race systemic lupus erythematosus ( SLE ; lupus ) .</brief_summary>
	<brief_title>Efficacy Safety Belimumab Black Race Patients With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>Study participant receive stable standard therapy lupus addition receive either placebo ( active medicine ) belimumab . The controlled period study 52 week . The random assignment study `` 2 1 '' mean every 3 participant , 2 receive belimumab 1 receive placebo . Participants successfully complete 52-week study may enter 6-month open-label extension . All participant open-label extension receive belimumab plus standard therapy .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Inclusion criterion : At least 18 year age . Selfidentified black race . Have clinical diagnosis SLE accord American College Rheumatology ( ACR ) criterion Have active SLE disease define SELENA SLEDAI score &gt; = 8 screening Have 2 unequivocally positive autoantibody test result define positive antinuclear antibody ( ANA ) test [ i.e. , titer &gt; = 1:80 human epithelial cell line 2 ( HEp2 ) immunofluorescence assay ( IFA ) and/or positive enzyme immunoassay ( EIA ) ] and/or positive anti double strand deoxyribonucleic acid ( dsDNA ) ( &gt; = 30 international unit [ IU ] /milliliter [ mL ] ) serum antibody test follow : From 2 independent time point within study screen period . Screening result must base study 's central laboratory result , OR One positive historical test result 1 positive test result screen period . Historical documentation positive ANA test ( e.g. , HEp2 IFA EIA ) antidsDNA ( eg , antidsDNA validate commercial assay ) must include date type test , name test laboratory , numerical reference range , key explains value provide positive versus negative OR negative , equivocal/borderline positive ) . Only unequivocally positive value define laboratory 's reference range acceptable ; borderline value accept . On stable SLE treatment regimen consist follow medication ( alone combination ) period least 30 day prior Day 0 ( i.e. , day 1st dose study agent ) : Corticosteroids ( prednisone prednisone equivalent , 40 mg/day ) : For subject SLE combination therapy , stable steroid dose must fix within range 0 40 mg/day ( prednisone prednisone equivalent ) . For subject whose SLE treatment steroid , stable steroid dose must fix within range 7.5 40 mg/day ( prednisone prednisone equivalent ) . For subject alternate day dos steroid , use average 2 daily dos calculate average daily steroid dose . Other immunosuppressive immunomodulatory agent include methotrexate , azathioprine , leflunomide , mycophenolate ( include mycophenolate mofetil , mycophenolate mofetil hydrochloride , mycophenolate sodium ) , calcineurin inhibitor ( e.g. , tacrolimus , cyclosporine ) , sirolimus , oral cyclophosphamide , 6mercaptopurine , mizoribine , thalidomide . Antimalarials ( e.g. , hydroxychloroquine , chloroquine , quinacrine ) . Nonsteroidal antiinflammatory drug ( NSAIDs ) . Note : Preexisting SLE medication must stable least 30 day prior Day 0 . Corticosteroids may add new medication dos adjust 30 day prior Day 0 . New SLE therapy corticosteroid must add within 60 day Day 0 . A female subject eligible enter study : Not pregnant nursing ; Of nonchildbearing potential define : premenopausal female document tubal ligation , hysterectomy , document hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion , document bilateral oophorectomy , OR postmenopausal define 12 month spontaneous amenorrhea appropriate clinical profile [ e.g. , &gt; 45 year , absence hormone replacement therapy cause amenorrhea ] ; questionable case obtain blood sample follicle stimulate hormone ( FSH ) estradiol simultaneously confirm . Diagnostic level FSH estradiol vary specific laboratories/assays ; OR childbearing potential negative pregnancy test determine serum human chorionic gonadotrophin ( hCG ) test screen urine hCG test prior dose AND agrees use one contraception method 2 week prior day dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 16 week follow last dose study agent . OR samesex partner , prefer usual lifestyle . Have ability understand requirement study , provide write informed consent ( include consent use disclosure researchrelated health information ) , comply study protocol procedure ( include require study visit ) . Exclusion criterion : Have receive treatment antiB lymphocyte stimulator ( BLyS ) [ belimumab ] time . Have receive follow within 364 day Day 0 : Abatacept Other B cell target therapy ( e.g. , rituximab , anticluster differentiation [ CD ] 20 agent , antiCD22 [ epratuzumab ] , antiCD52 [ alemtuzumab ] , BLySreceptor fusion protein [ BR3 ] , TACIFc , antiBcell activate factor [ BAFF ] ( LY2127399 ) . A biologic investigational agent B cell target therapy ( e.g. , abetimus sodium , antiCD40L antibody [ BG9588/IDEC131 ] ) . Have require 3 course systemic corticosteroid concomitant condition ( e.g. , asthma , atopic dermatitis ) within 364 day Day 0 . ( Topical inhale steroid permit . ) Have receive follow within 90 day Day 0 : Antitumor necrosis factor ( TNF ) therapy ( eg , adalimumab , certolizumab pegol , etanercept , golimumab , infliximab ) . Intravenous ( IV ) cyclophosphamide Interleukin1 receptor antagonist ( anakinra ) . Intravenous immunoglobulin ( IVIG ) . High dose prednisone equivalent ( &gt; 100 mg/day ) . Plasmapheresis . Have receive follow within 60 day Day 0 : A nonbiologic investigational agent . Any new immunosuppressive/immunomodulatory agent , antimalarial , NSAID Note : New inhale topical steroid new topical immunosuppressive agent ( e.g. , eye drop , topical cream ) allow . Any NSAID use &lt; 1 week allow . Any steroid injection ( e.g. , intramuscular , intraarticular , intravenous ) . Have receive follow within 30 day Day 0 : A live vaccine . A change dose corticosteroid , immunosuppressive/immunomodulatory agent , antimalarial , NSAID Have severe lupus kidney disease ( define proteinuria &gt; 6 grams/24 hour equivalent use spot urine protein creatinine ratio , serum creatinine &gt; 2.5 mg/deciliter [ dL ] ) , severe active nephritis require acute therapy permit protocol ( e.g. , IV cyclophosphamide within 90 day Day 0 ) , require hemodialysis highdose prednisone ( &gt; 100 mg/day ) within 90 day Day 0 . Have severe active central nervous system ( CNS ) lupus ( include seizure , psychosis , organic brain syndrome , cerebrovascular accident [ CVA ] , cerebritis , CNS vasculitis ) require therapeutic intervention within 60 day Day 0 . Have history major organ transplant ( e.g. , heart , lung , kidney , liver ) hematopoietic stem cell/marrow transplant . Have clinical evidence significant unstable uncontrolled acute chronic disease due SLE ( i.e. , cardiovascular , pulmonary , hematologic , gastrointestinal , hepatic , renal , neurological , malignancy , infectious disease ) , opinion principal investigator , could confound result study put subject undue risk . Have plan surgical procedure history medical disease ( e.g. , cardiopulmonary ) , laboratory abnormality , condition ( e.g. , poor venous access ) , opinion principal investigator , make subject unsuitable study . Have history malignant neoplasm within last 5 year , except adequately treat cancer skin ( basal squamous cell ) carcinoma situ uterine cervix . Have require management acute chronic infection , follow : Currently suppressive therapy chronic infection ( tuberculosis , pneumocystis , cytomegalovirus , herpes simplex virus , herpes zoster , atypical mycobacteria ) . Hospitalization treatment infection within 60 day Day 0 . Use parenteral ( IV intramuscular [ IM ] ) antibiotic ( antibacterial , antiviral , antifungal , antiparasitic agent ) within 60 day Day 0 . Subjects evidence serious suicide risk include history suicidal behavior last 6 month and/or suicidal ideation type 4 5 screen ColumbiaSuicide Severity Rating Scale ( CSSRS ) last 2 month , investigator 's opinion , pose significant suicide risk . Have current drug alcohol abuse dependence , history drug alcohol abuse dependence within 364 day prior Day 0 . Have historically positive test test positive screening human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody , hepatitis C antibody . Have immunoglobulin ( Ig ) A deficiency ( IgA level &lt; 10 mg/dL ) . Have grade 3 great laboratory abnormality base adverse event Severity grading table except follow allow : Stable grade 3 prothrombin time ( PT ) secondary anticoagulant , e.g. , warfarin , treatment . Stable grade 3 partial thromboplastin time ( PTT ) due lupus anticoagulant relate liver disease anticoagulant therapy . Stable grade 3/4 proteinuria ( &lt; =6 grams/24 hour equivalent spot urine protein creatinine ratio allow ) . Stable grade 3 hypoalbuminemia due lupus nephritis , relate liver disease malnutrition . Stable grade 3 gamma glutamyl transferase ( GGT ) elevation due lupus hepatitis , relate alcoholic liver disease , uncontrolled diabetes , viral hepatitis . If present , abnormality alanine transaminase ( ALT ) and/or aspartate transaminase ( AST ) must &lt; =grade 2 . Stable grade 3 hemoglobin reduction due lupus . Stable grade 3 neutropenia stable grade 3 white blood cell count . Have history anaphylactic reaction parenteral administration contrast agent , human murine protein , monoclonal antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>African Continental Ancestry Group</keyword>
	<keyword>Autoimmune Disease</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Minority Groups</keyword>
	<keyword>Black Race</keyword>
	<keyword>African Americans</keyword>
	<keyword>SLE</keyword>
	<keyword>Belimumab</keyword>
	<keyword>Lupus</keyword>
</DOC>